trending Market Intelligence /marketintelligence/en/news-insights/trending/dr_nlgdh2zmazvntrvjvgg2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Allergan adds new director to board


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Allergan adds new director to board

Allergan PLC appointed a new director to its board as part of an ongoing refreshment process.

Michael Greenberg the fifth new director to join the Dublin-based pharmaceutical company's board in the last 18 months has nearly 35 years of experience in neurobiology, Allergan said in a statement.

Greenberg is a professor of neurobiology at Harvard University and the co-lead of the Allen Discovery Center for Human Brain Evolution at Harvard Medical School.

"With our focus on central nervous system therapies and our goal of harnessing the best science from across the innovation ecosystem, Dr. Michael Greenberg will be a great addition to our board," Allergan Chairman and CEO Brent Saunders said in a statement.

Meanwhile, Fred Weiss will be retiring from the Allergan board in October. He has been serving on the board since 2000 and is the company's longest-serving board member.

Allergan will have 12 members on its board following the moves, of which 10 will be independents.

Allergan has commercial operations in almost 100 countries around the world. It focuses on the development, manufacturing and commercializing of products for skin care, eye care, women health, heart diseases, reproductive systems, and infections.